How Does Veozah Work and What Does It Do in Your Brain?

Your brain has a temperature-control center

The hypothalamus helps keep body temperature within a narrow range. It receives information from the body, compares that information with the range it is defending, and coordinates responses such as sweating, widening blood vessels near the skin, shivering and narrowing those vessels.

During the menopause transition, declining and fluctuating ovarian hormones alter signaling involving specialized hypothalamic neurons called KNDy neurons. Their name comes from three signaling molecules: kisspeptin, neurokinin B and dynorphin. These neurons are closely connected to the circuits that regulate temperature.

When estrogen signaling declines, neurokinin B activity through NK3 receptors becomes more prominent within this network. The temperature-control system can become more reactive, so a small temperature shift may trigger a full heat-loss response: flushing, sweating and sometimes a change in heart rate. Our page on what happens in the brain during a hot flash explains that response in more detail.

What blocking an NK3 receptor changes

Fezolinetant is an NK3 receptor antagonist. By occupying and blocking those receptors, it reduces neurokinin B signaling in the hypothalamic network involved in hot flashes. Clinical trials found that fezolinetant reduced the frequency and severity of moderate to severe vasomotor symptoms compared with placebo.

This mechanism is narrower than hormone therapy. Menopausal hormone therapy supplies estrogen, with a progestogen when needed, and affects multiple estrogen-responsive tissues. Veozah does not restore estrogen signaling. That distinction is why it is described as a nonhormonal hot-flash treatment, including for some women who cannot or prefer not to use hormone therapy.

What Veozah does not do in the brain

Veozah is not a treatment for brain fog, memory loss, mood disorders, migraine or dementia prevention. If reducing night sweats leads to less fragmented sleep, a woman may feel more alert the next day; that would be an indirect benefit of better sleep, not evidence that fezolinetant directly improves cognition or protects the brain.

Safety belongs in the mechanism conversation too

Fezolinetant is processed by the liver, and rare serious liver injury has been reported. The FDA-approved prescribing information requires liver blood tests before treatment and follow-up monitoring. A prescriber also needs to review other medications and health conditions because some combinations and conditions make fezolinetant inappropriate.

Contact the prescribing clinician promptly if symptoms that could indicate liver injury develop, such as unusual fatigue, nausea, poor appetite, itching, yellowing of the skin or eyes, dark urine, pale stools, or pain in the upper right abdomen. Do not start, stop or change a prescription based on this page.